Clinical Trial Update: Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL [Phase 2]

View source ↗

Summary

Phase 2 open-label clinical trial assessing lenalidomide with MOR00208 in diffuse large B-cell lymphoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• MOR00208

Snippet

Sponsor: MorphoSys AG | Conditions: Diffuse Large B-cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2020-02-05